The U.S. military has lessened its stringent health requirements to cope with lagging recruitment numbers, contributing to an ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...

Eli Lilly & Co. sees 60% sales increase for weight-loss drug in India, tapping into growing demand for anti-obesity solutions ...

The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm ...

The average woman's weight can vary depending on age, physical traits, certain health conditions, metabolism, appetite, and ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...

While Americans understand the benefits of GLP-1 agonist medications, 83% of Americans are unwilling to pay more than $100 in ...

Obesity — like most other medical conditions — requires an “arsenal” of treatments, rather than a one-size-fits-all approach.

Meharry Medical College announced the formation of its “Office of Memphis Programs” at a ribbon-cutting on June 9.

Tirzepatide is the first dual-target therapy that activates both GIP and GLP-1 receptors, helping manage blood sugar levels ...

The Obesity Association™, a division of the American Diabetes Association®, (Obesity Association), with inaugural support from Novo Nordisk Inc., is taking the next step toward improved obesity care.